SANOFICONR4,180.00

Sanofi Consumer Healthcare India Limited

· Pharma & Health
AnnualQuarterly₹ CrorePeersPGHLSANOFISENORESINNOVACAPMOREPENLABIOLCPFDCASTRAZENMcap ₹9,614 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations164.4159.9170.7172.6220.9233.9251.0229.2235.7
Other Income0.84.25.05.25.63.04.65.66.3
Total Income165.2164.1175.7177.8226.5236.9255.6234.8242.0
Expenses
+ Cost of Materials Consumed31.714.114.818.955.436.549.940.247.5
+ Purchases of Stock-in-Trade0.014.418.433.54.626.06.118.116.0
+ Changes in Inventories13.810.28.7-13.61.2-0.712.3-2.1-7.2
+ Employee Benefit Expense24.827.427.629.632.031.735.533.131.3
+ Finance Costs0.13.40.40.40.50.60.50.50.4
+ Depreciation & Amortisation1.11.51.02.03.03.33.43.23.3
+ Other Expenses30.530.739.140.257.555.457.451.158.8
Total Expenses102.0101.7110.0111.0154.2152.8165.1144.1150.1
EBITDA63.663.162.164.070.285.089.888.889.3
EBIT62.561.661.162.067.281.786.485.686.0
Profit
PBT before Exceptional Items63.262.465.766.872.384.190.590.791.9
+ Exceptional Items-24.3-1.2-2.90.06.60.00.00.00.0
Pretax Income38.961.262.866.878.984.190.590.791.9
+ Current Tax13.016.917.617.018.422.524.124.123.4
+ Deferred Tax-3.1-0.70.9-0.2-0.2-1.3-0.1-1.2-0.3
Tax Expense9.916.218.516.818.221.224.022.923.1
Net Income29.045.044.350.060.762.966.567.868.8
+ Net Income — Continuing Ops29.045.044.350.060.762.966.567.868.8
+ Other Comprehensive Income0.00.0-1.40.00.00.0-1.40.00.0
Total Comprehensive Income29.045.042.950.060.762.965.167.868.8
Per Share
Basic EPS12.5819.5419.2521.6926.3627.3128.8729.4429.87
Diluted EPS12.5819.540.000.0026.3627.3128.8729.4429.87
Other Comprehensive Income — detail
+ Other Comprehensive Income0.0-1.40.0
+ Items NOT to be Reclassified to P&L-1.9-1.9
+ Tax on Items NOT to be Reclassified0.0-0.50.0
+ Tax on Items NOT to be Reclassified — alt tag-0.5
Comprehensive Income — Owners of Parent0.045.00.0
Per Share — as-filed variants
Basic EPS — Continuing Operations12.5819.5419.2521.6926.3627.3128.8729.4429.87
Diluted EPS — Continuing Operations12.5819.540.000.0026.3627.3128.8729.4429.87
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period212.0147.1147.2
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit118.9121.2128.8133.8159.7172.1182.7173.0179.4
Gross Margin %72.3275.8075.4577.5272.3073.5872.7975.4876.11
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)63.262.465.766.872.384.190.590.791.9
− Exceptional Items (reconciliation)-24.3-1.2-2.90.06.60.00.00.00.0
Net Income Adj (tax-effected)47.145.946.350.055.662.966.567.868.8
EPS Adj20.4419.9220.1421.6924.1527.3128.8729.4429.87
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.00230.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital23.023.023.023.023.023.023.023.023.0
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.